Together, the results of the Annexin V apoptosis assay, caspase-3/7 activity assay, and immunoblots for cleaved caspase-3 and PARP make it likely that the observed reduction in viability seen in multiple myeloma cells treated with cPLA2α inhibitors is due to induction of apoptosis. The gene discussed is ANXA5; the disease is plasma cell myeloma.